


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.90%
+9.19%
+2.92%
+2.30%
-1.97%
EW
Edwards Lifesciences
$83.60
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
EW Price Performance
$86.21 (-3.03%)
$82.45 (+1.39%)
$80.89 (+3.35%)
$75.82 (+10.26%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
EW Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
EW Street Sentiment is extremely bullish but have mixed views on the near-term outlook
EW has Low risk level

Average key support and resistance price levels
EW
Edwards Lifesciences
83.60
-0.80%
PINS
23.41
-9.61%
PRM
Perimeter Solutions SA
26.73
-2.87%
CHDN
Churchill Downs
100.23
-1.22%
F
Ford Motor
13.93
+3.65%
What is EW current stock price?
What are EW stock strengths?
What is EW Risk Level?
What is EW market cap and volume?
What is EW current Stock IQ?
Should I buy EW stock right now?
Is EW a Strong Buy right now?
What does a 'Strong Buy' rating mean for EW?
What does a 'Strong Sell' rating mean for EW?
What factors influence EW's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.90%
+9.19%
+2.92%
+2.30%
-1.97%
EW
Edwards Lifesciences
Current Price
$83.60
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
Recently Viewed
EW
Edwards Lifesciences
83.60
-0.80%
PINS
23.41
-9.61%
PRM
Perimeter Solutions SA
26.73
-2.87%
CHDN
Churchill Downs
100.23
-1.22%
F
Ford Motor
13.93
+3.65%

EW Price Performance
$86.21 (-3.03%)
$82.45 (+1.39%)
$80.89 (+3.35%)
$75.82 (+10.26%)
EW Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
EW Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
EW Street Sentiment is extremely bullish but have mixed views on the near-term outlook
EW has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
BUY
Jan 10, 2026
Upgrade
Buy
TD Cowen
Dec 19, 2025
Upgrade
Overweight
JP Morgan
Dec 18, 2025
Reiterate
Hold
Canaccord Genuity
Dec 16, 2025
Reiterate
Neutral
Baird
Dec 12, 2025
Reiterate
Buy
Citigroup
EW Stock IQ
EW Latest Analysis
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?. EW benefits from strong TAVR and TMTT momentum but macro pressures and FX headwinds cloud the near-term outlook.
Wed Jan 14, 2026
Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Mon Jan 12, 2026
Court Ruling Ends Edwards Lifesciences $1.2 Billion Plan To Acquire JenaValve. On Friday the United States District Court for the District of Columbia granted the motion from the United States Federal Trade Commission (FTC) for an injunction blocking ) proposed acquisition of As a result Edwards JenaValve.Edwards said it disagrees with the decision and believes that the acquisition would have been in the best interest of a large growing and underserved group of patients.Aortic regurgitation (AR
Mon Jan 12, 2026
US FTC wins ruling blocking Edwards Lifesciences acquisition of JenaValve.
Fri Jan 9, 2026
FTC wins ruling blocking Edwards Lifesciences acquisition of JenaValve.
Fri Jan 9, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.